When was Lonza founded?

Lonza was founded in 1897 and raised its 1st funding round 113 years after it was founded.

Where is Lonza located?

Lonza is headquartered in Basel, Switzerland. It is registered at Morristown, New Jersey.

How many employees does Lonza have?

As of Mar 31, 2026, the latest employee count at Lonza is 6848.

Is Lonza a funded company?

Lonza is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Nov 09, 2010.

When was the latest funding round of Lonza?

Lonza's latest funding was a $***** Post IPO round on Nov 25, 2023, with participation from 1 investor.

What is the annual revenue of Lonza?

Annual revenue of Lonza is £306 as on Aug 31, 2024.

Where does Lonza rank among its competitors?

Lonza ranks 4th amongst 759 active competitors, of which 42 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Shenshi Technology, which secured $114M in Dec, 2025.

Who are the top competitors of Lonza?

Lonza's top competitors include Pfizer, Pharmaron and Boehringer Ingelheim. Among them, Shenshi Technology secured the most recent funding round in December, 2025.

Lonza - 2026 Company Profile, Funding, Competitors & Financials

Lonza is an acquired company based in Basel (Switzerland), founded in 1897. It operates as a Provider of CDMO services to pharma, biotech, and specialty ingredient markets. Lonza has raised an undisclosed amount in funding. The company has 759 active competitors, including 42 funded and 72 that have exited. Its top competitors include companies like Pfizer, Pharmaron and Boehringer Ingelheim.

Company Details

Provider of CDMO services to pharma, biotech, and specialty ingredient markets. The company offers a complete range of development and manufacturing services for fine chemicals, advanced intermediates, active pharmaceutical ingredients (APIs), biologics, and functional ingredients. They claim to offer synergies between chemical synthesis and biotechnology to enable the production of tailor-made intermediates and APIs for use as pharmaceuticals, biotherapies, nutraceuticals, and cosmetics. Their proprietary platforms and development technologies such as GS Gene enable them to offer customized biological and chemical manufacturing solutions. In 2022, the company recorded annual revenues of $6.52B and a net profit of $1.27B.

Website: www.lonza.com/
Social
Email ID: *****@lonza.com
Registered Address: Morristown, New Jersey

Key Metrics

Founded Year

1897

Location

Basel, Switzerland

Stage

Acquired

Latest Funding Round

Post IPO, Nov 25, 2023, $*****

Investors

Defense.gov & 5 more

Ranked

4^th among 759 active competitors

Annual Revenue

£306 as on Aug 31, 2024

Employee Count

6,848 as on Mar 31, 2026

Investment & Acquisitions

Synaffix & 18 more

Similar Companies

Pfizer & 818 more

Exit Details

Acquired by SBI Mutual Fund (Feb 15, 2024)

View Lonza's full profile

Lonza is associated with 10 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Bomi Wood s.r.o. CIN: 02703581 , Czech Republic, Active	Feb 25, 2014	-	-
LONZA CIN: 40103809594 , Latvia, Deadpooled	Jul 21, 2014	$786K (As on Dec 31, 2015)	5 (As on Dec 31, 2015)	-
Lonza India Private Limited CIN: U24230HR1999PTC095355 , India, Active	Jan 25, 1999	$5.88K (As on Mar 31, 2025)	-
ARCH PROTECTION CHEMICALS PRIVATE LIMITED CIN: U74930MH2010FTC207485 , India, Active	Sep 07, 2010	$14.4M (As on Mar 31, 2025)	33 (As on Aug 31, 2024)
Lonza Group CIN: CHE-106.841.866 , Switzerland, Active		$6.52B (As on Dec 31, 2022)	-	-
LENZA WORLD LIMITED CIN: 12844264 , United Kingdom, Active	Aug 27, 2020	$386 (As on Aug 31, 2024)	-
LONZA FINANCE INTERNATIONAL NV CIN: 0736.673.428 , Belgium, Active	Oct 22, 2019	-	-	-
Lonza Inc. CIN: 135665861 , United States, Active	Dec 26, 999	-	973 (As on Dec 31, 2024)	-
CAPSUGEL HEALTHCARE PRIVATE LIMITED CIN: U85110HR1982PTC020151 , India, Active	Dec 13, 1982	$40.3M (As on Mar 31, 2025)	-
Manuscript Manufactory s.r.o. CIN: 17139422 , Czech Republic, Active	May 12, 2022	-	-

Lonza got acquired by SBI Mutual Fund on Feb 15, 2024.

Click here to take a look at Lonza's acquisition in detail

Lonza has raised funding over 6 rounds. Its first funding round was on Nov 09, 2010. Its latest funding round was a Post IPO round on Nov 25, 2023 for $*****. 1 investor participated in its latest round. Lonza has 6 institutional investors.

Here is the list of recent funding rounds of Lonza:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 25, 2023	4586101	Post IPO	3833635	2087627	5897055	6539508
May 12, 2022	1422123	Post IPO	8870629	1366240	4756908	ALSA Ventures
Jan 01, 2019	1826960	Grant (prize money)	3524388	8638219	2410724	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Lonza's funding rounds and investors

Lonza's employee count trend

Lonza has 6,848 employees as of Mar 26. Here is Lonza's employee count trend over the years:

Uncover Lonza's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lonza include Pfizer, Pharmaron and Boehringer Ingelheim. Here is the list of Top 10 competitors of Lonza, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Pfizer 1849, New York City (United States), Public	Provider of pharmaceutical products for multiple disease treatments	-	Berkshire Hathaway, Alcor Fund & 16 others	79/100
2nd	Pharmaron 2003, Beijing (China), Public	Suite of drug discovery and development services for small molecules	$320M	Gl-investment, Legend Capital & 11 others	76/100
3rd	Boehringer Ingelheim 1885, Ingelheim am Rhein (Germany), Funding Raised	Provider of generic drugs and clinical research services	-	Amgen Business Development, Sanderling Ventures ... & 1 others	64/100
4th	Lonza 1897, Basel (Switzerland), Acquired	Provider of CDMO services to pharma, biotech, and specialty ingredient markets	-	Defense.gov, Upekkha & 4 others	59/100
5th	Tyra 2018, Carlsbad (United States), Public	Developer of cancer resistance therapies	$156M	Boxer Capital, RA Capital Management & 6 others	59/100
6th	LabConnect 2002, Johnson City (United States), Series A	Provider of laboratory testing, clinical ttrial research, and biopharma functional services	$29.2M	Broadoak Capital Partners, ABS Capital & 5 others	58/100
7th	Clearsynth 2009, Mumbai (India), Series A	CDMO focused on manufacturing of pharmaceutical small molecules and analytical research services	$4.81M	SIDBI Venture Capital, Tulip Diagnostics & 7 others	58/100
8th	Shenshi Technology 2019, Beijing (China), Series C	Developer of AI-driven platform and tools for scientific research and development	$255M	Source Code Capital, Qiming Venture Partners ... & 22 others	58/100
9th	Matchpoint Therapeutics 2021, Cambridge (United States), Series A	Provider of small molecular medicine development and analytics services	$100M	Access Industries, Sanofi Ventures & 4 others	55/100
10th	Evergreen Theragnostics 2019, Jersey City (United States), Acquired	Provider of radiopharmaceuticals manufacturing and regulatory services	$75.9M	Petrichor, Novacapital & 4 others	52/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Lonza's competitors? Click here to see the top ones

Lonza has made 5 investments in companies including Affinia Therapeutics and Affinia Therapeutics. Lonza has also acquired 14 companies including Synaffix and Octane.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jun 01, 2023	Acquisition	Synaffix	2010	Nijmegen (Netherlands)
Apr 20, 2021	Investments	Affinia Therapeutics	2019	Waltham (United States)
Mar 12, 2020	Investments	Affinia Therapeutics	2019	Waltham (United States)